A BLA filing for ifinatamab deruxtecan was voluntarily withdrawn in previously treated extensive-stage small cell lung cancer. The decision reshapes the near-term regulatory path for the ADC in a setting with limited options and underscores how quickly clinical and regulatory expectations can change when confirmatory evidence is still evolving.